Clodronic acid
As of the edition of 20 October 2026, Clodronic acid is a small molecule: marketed, first approved in 2002 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Clasteon
- First approved
- 1 May 2002 (CA)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Knight Therapeutics
- Registered trials
- 10, 1 stopped early
- Disease areas
- Cancer; Bones, joints and muscles; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 5 | 4 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Knight Therapeutics | Applicant | 2002 to now |